XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Xencor Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.19+0.34 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $1.76B
- P/E (TTM)
- –
- Dividend yield
- –
Xencor statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Xencor | Industry median |
|---|---|---|
| Market Cap | $1.72B | $166.30M |
| Enterprise Value | $1.78B | $88.19M |
| PS Ratio | 16.43 | 3.65 |
| PB Ratio | 3.43 | 2.03 |
| P/TBV Ratio | 3.47 | 2.29 |
Enterprise value
| Measure | Xencor | Industry median |
|---|---|---|
| EV / Sales | 17.00 | 2.51 |
Income (trailing twelve months)
| Measure | Xencor | Industry median |
|---|---|---|
| Revenue | $104.97M | $58.34M |
| Operating Income | -$216.08M | -$21.40M |
| Pretax Income | -$160.85M | -$14.34M |
| Net Income | -$163.33M | -$22.46M |
| EBITDA | -$206.23M | -$16.91M |
| EPS (Diluted) | -$2.17 | -$0.83 |
Margins
| Measure | Xencor | Industry median |
|---|---|---|
| Operating Margin | -205.8% | -44.0% |
| Pretax Margin | -153.2% | -13.3% |
| Profit Margin | -155.6% | -40.2% |
| EBITDA Margin | -196.5% | -30.2% |
| FCF Margin | -198.4% | -9.27% |
Returns
| Measure | Xencor | Industry median |
|---|---|---|
| Return on Equity (ROE) | -29.1% | -53.2% |
| Return on Assets (ROA) | -20.4% | -40.9% |
| Return on Invested Capital (ROIC) | -26.6% | -32.4% |
| Return on Capital Employed (ROCE) | -33.6% | -38.1% |
Growth
| Measure | Xencor | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -28.6% | 5.96% |
| Revenue Growth (3Y CAGR) | -8.62% | 2.25% |
| Revenue Growth (5Y CAGR) | 0.47% | 6.48% |
Balance sheet
| Measure | Xencor | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $44.66M | $61.43M |
| Total Debt | $104.90M | $118.52M |
| Net Cash (Debt) | -$60.23M | $15.35M |
| Net Cash Per Share | -$0.81 | $0.66 |
| Equity (Book Value) | $503.23M | $49.09M |
| Book Value Per Share | $6.77 | $1.37 |
| Tangible Book Value | $496.70M | $23.52M |
| Working Capital | $441.35M | $76.81M |
Financial position
| Measure | Xencor | Industry median |
|---|---|---|
| Current Ratio | 6.39 | 3.34 |
| Quick Ratio | 1.06 | 2.44 |
| Debt / Equity | 0.21 | 0.52 |
| Interest Coverage | -7.98 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Xencor | Industry median |
|---|---|---|
| Operating Cash Flow | -$205.81M | -$12.35M |
| Capital Expenditures | -$2.47M | -$1.08M |
| Free Cash Flow | -$208.29M | -$20.22M |
| FCF Per Share | -$2.80 | -$0.42 |
Efficiency
| Measure | Xencor | Industry median |
|---|---|---|
| Asset Turnover | 0.13 | 0.39 |
| Revenue Per Employee | $403.74K | $404.87K |
| Profits Per Employee | -$628.17K | -$703.34K |
| Employee Count | 260 | 74 |
Dividends and yields
| Measure | Xencor | Industry median |
|---|---|---|
| Earnings Yield | -9.47% | -23.3% |
| FCF Yield | -12.1% | -8.72% |
Shares
| Measure | Xencor | Industry median |
|---|---|---|
| Shares Outstanding | 74,353,400 | 58,127,000 |
| Shares Change (YoY) | 5.23% | 10.9% |
| Shares Change (QoQ) | 0.36% | 0.54% |
| Float | 73,157,800 | 49,136,700 |
| Shares Held by Insiders | 1.61% | 11.6% |
| Shares Held by Institutions | 113.2% | 59.4% |
Taxes
| Measure | Xencor | Industry median |
|---|---|---|
| Income Tax | $2.48M | $79.87K |
Scores
| Measure | Xencor | Industry median |
|---|---|---|
| Altman Z-Score | 2.73 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Xencor's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.